Vaxil Total Operating Expenses vs Ebit Analysis

VXL Stock

CAD 0.01 0.00 0.00%

Vaxil Bio financial indicator trend analysis is much more than just breaking down Vaxil Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxil Bio is a good investment. Please check the relationship between Vaxil Bio Total Operating Expenses and its Ebit accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Operating Expenses vs Ebit

Total Operating Expenses vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxil Bio Total Operating Expenses account and Ebit. At this time, the significance of the direction appears to have pay attention.

The correlation between Vaxil Bio's Total Operating Expenses and Ebit is -1.0. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Ebit in the same time period over historical financial statements of Vaxil Bio, assuming nothing else is changed. The correlation between historical values of Vaxil Bio's Total Operating Expenses and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Vaxil Bio are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Total Operating Expenses i.e., Vaxil Bio's Total Operating Expenses and Ebit go up and down completely randomly.

Correlation Coefficient

-1.0

Relationship Direction	Negative
Relationship Strength	Strong

View All Relationships

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Ebit

Most indicators from Vaxil Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to drop to 114.00 in 2024. Enterprise Value Over EBITDA is likely to climb to -9.3 in 2024

	2021	2022	2023	2024 (projected)
Total Operating Expenses	986K	584K	254.0	241.3
Cost Of Revenue	25K	2K	1.8K	1.7K

Total Operating Expenses Cost Of Revenue

Vaxil Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Property Plant Equipment	Short Term Investments
Total Assets		0.6	0.35	0.9	-0.46	-0.99	-0.66	0.05	0.99	-0.46	0.99	0.61	0.71	-0.1	-0.48	0.34	0.99	0.65	-0.17	0.78	0.16	-0.06	-0.44	0.01	-0.45	-0.06
Other Current Liab	0.6		0.42	0.47	-0.41	-0.56	-0.34	-0.17	0.59	-0.41	0.59	0.4	0.33	0.42	-0.37	0.39	0.62	0.3	-0.01	0.37	0.23	0.22	-0.32	0.17	-0.52	0.22
Total Current Liabilities	0.35	0.42		-0.09	-0.3	-0.3	-0.55	0.81	0.35	-0.3	0.35	0.47	0.32	0.25	-0.05	1.0	0.38	0.36	0.5	0.03	0.49	0.37	-0.58	0.47	0.0	0.37
Total Stockholder Equity	0.9	0.47	-0.09		-0.31	-0.89	-0.39	-0.33	0.88	-0.31	0.88	0.42	0.55	-0.2	-0.44	-0.1	0.87	0.51	-0.43	0.75	-0.08	-0.13	-0.15	-0.24	-0.46	-0.13
Property Plant And Equipment Net	-0.46	-0.41	-0.3	-0.31		0.56	0.73	-0.08	-0.54	1.0	-0.54	-0.45	-0.7	-0.15	0.45	-0.28	-0.56	-0.66	-0.16	-0.65	-0.7	0.35	0.87	-0.45	0.83	0.35
Net Debt	-0.99	-0.56	-0.3	-0.89	0.56		0.72	-0.02	-0.99	0.56	-0.99	-0.6	-0.78	0.16	0.51	-0.29	-0.99	-0.71	0.16	-0.84	-0.22	0.18	0.52	-0.04	0.54	0.18
Retained Earnings	-0.66	-0.34	-0.55	-0.39	0.73	0.72		-0.39	-0.7	0.73	-0.7	-0.63	-0.94	0.12	0.58	-0.55	-0.71	-0.86	-0.24	-0.79	-0.53	0.38	0.84	-0.33	0.52	0.38
Accounts Payable	0.05	-0.17	0.81	-0.33	-0.08	-0.02	-0.39		0.06	-0.08	0.06	0.32	0.15	0.04	0.18	0.83	0.07	0.21	0.43	-0.17	0.36	0.26	-0.43	0.32	0.3	0.26
Cash	0.99	0.59	0.35	0.88	-0.54	-0.99	-0.7	0.06		-0.54	1.0	0.6	0.75	-0.15	-0.46	0.35	1.0	0.71	-0.12	0.8	0.23	-0.07	-0.51	0.06	-0.5	-0.07
Non Current Assets Total	-0.46	-0.41	-0.3	-0.31	1.0	0.56	0.73	-0.08	-0.54		-0.54	-0.45	-0.7	-0.15	0.45	-0.28	-0.56	-0.66	-0.16	-0.65	-0.7	0.35	0.87	-0.45	0.83	0.35
Cash And Short Term Investments	0.99	0.59	0.35	0.88	-0.54	-0.99	-0.7	0.06	1.0	-0.54		0.6	0.75	-0.15	-0.46	0.35	1.0	0.71	-0.12	0.8	0.23	-0.07	-0.51	0.06	-0.5	-0.07
Net Receivables	0.61	0.4	0.47	0.42	-0.45	-0.6	-0.63	0.32	0.6	-0.45	0.6		0.54	0.15	-0.13	0.46	0.63	0.48	-0.04	0.51	0.35	-0.05	-0.58	0.11	-0.33	-0.05
Common Stock Shares Outstanding	0.71	0.33	0.32	0.55	-0.7	-0.78	-0.94	0.15	0.75	-0.7	0.75	0.54		-0.24	-0.69	0.3	0.74	0.85	0.01	0.89	0.3	-0.52	-0.7	0.08	-0.65	-0.52
Other Current Assets	-0.1	0.42	0.25	-0.2	-0.15	0.16	0.12	0.04	-0.15	-0.15	-0.15	0.15	-0.24		-0.2	0.23	-0.06	-0.24	-0.01	-0.19	0.2	0.2	-0.06	0.16	-0.18	0.2
Other Stockholder Equity	-0.48	-0.37	-0.05	-0.44	0.45	0.51	0.58	0.18	-0.46	0.45	-0.46	-0.13	-0.69	-0.2		-0.02	-0.49	-0.48	0.13	-0.69	-0.05	0.55	0.32	0.07	0.61	0.55
Total Liab	0.34	0.39	1.0	-0.1	-0.28	-0.29	-0.55	0.83	0.35	-0.28	0.35	0.46	0.3	0.23	-0.02		0.37	0.35	0.53	0.02	0.51	0.37	-0.58	0.5	0.05	0.37
Total Current Assets	0.99	0.62	0.38	0.87	-0.56	-0.99	-0.71	0.07	1.0	-0.56	1.0	0.63	0.74	-0.06	-0.49	0.37		0.7	-0.13	0.79	0.26	-0.07	-0.53	0.08	-0.53	-0.07
Common Stock	0.65	0.3	0.36	0.51	-0.66	-0.71	-0.86	0.21	0.71	-0.66	0.71	0.48	0.85	-0.24	-0.48	0.35	0.7		0.1	0.76	0.35	-0.29	-0.65	0.17	-0.51	-0.29
Short Long Term Debt Total	-0.17	-0.01	0.5	-0.43	-0.16	0.16	-0.24	0.43	-0.12	-0.16	-0.12	-0.04	0.01	-0.01	0.13	0.53	-0.13	0.1		-0.17	0.59	0.1	-0.41	0.86	0.18	0.1
Net Tangible Assets	0.78	0.37	0.03	0.75	-0.65	-0.84	-0.79	-0.17	0.8	-0.65	0.8	0.51	0.89	-0.19	-0.69	0.02	0.79	0.76	-0.17		0.27	-0.61	-0.57	0.05	-0.67	-0.61
Current Deferred Revenue	0.16	0.23	0.49	-0.08	-0.7	-0.22	-0.53	0.36	0.23	-0.7	0.23	0.35	0.3	0.2	-0.05	0.51	0.26	0.35	0.59	0.27		-0.07	-0.87	0.88	-0.28	-0.07
Deferred Long Term Liab	-0.06	0.22	0.37	-0.13	0.35	0.18	0.38	0.26	-0.07	0.35	-0.07	-0.05	-0.52	0.2	0.55	0.37	-0.07	-0.29	0.1	-0.61	-0.07		0.25	0.02	0.44	1.0
Short Long Term Debt	-0.44	-0.32	-0.58	-0.15	0.87	0.52	0.84	-0.43	-0.51	0.87	-0.51	-0.58	-0.7	-0.06	0.32	-0.58	-0.53	-0.65	-0.41	-0.57	-0.87	0.25		-0.65	0.54	0.25
Short Term Debt	0.01	0.17	0.47	-0.24	-0.45	-0.04	-0.33	0.32	0.06	-0.45	0.06	0.11	0.08	0.16	0.07	0.5	0.08	0.17	0.86	0.05	0.88	0.02	-0.65		-0.06	0.02
Property Plant Equipment	-0.45	-0.52	0.0	-0.46	0.83	0.54	0.52	0.3	-0.5	0.83	-0.5	-0.33	-0.65	-0.18	0.61	0.05	-0.53	-0.51	0.18	-0.67	-0.28	0.44	0.54	-0.06		0.44
Short Term Investments	-0.06	0.22	0.37	-0.13	0.35	0.18	0.38	0.26	-0.07	0.35	-0.07	-0.05	-0.52	0.2	0.55	0.37	-0.07	-0.29	0.1	-0.61	-0.07	1.0	0.25	0.02	0.44

Click cells to compare fundamentals

Vaxil Bio Account Relationship Matchups

Vaxil Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	205K	1.7M	2.3M	1.5M	976K	853.8K
Other Current Liab	63K	260K	584.4K	404.6K	84.9K	80.7K
Total Current Liabilities	777K	857K	585K	405K	85K	80.8K
Total Stockholder Equity	(583K)	804K	1.7M	1.1M	891K	446.7K
Property Plant And Equipment Net	118K	62K	95K	27K	2K	0.0
Net Debt	(66K)	(1.5M)	(2.2M)	(1.5M)	(938K)	(984.9K)
Retained Earnings	(16.2M)	(17.5M)	(18.5M)	(19.1M)	(19.4M)	(18.4M)
Accounts Payable	618K	588K	559.0	394.0	85.0	80.75
Cash	753K	83K	1.5M	2.2M	938K	665.5K
Non Current Assets Total	118K	62K	95K	27K	2K	0.0
Cash And Short Term Investments	753K	83K	1.5M	2.2M	938K	665.5K
Net Receivables	11K	33K	35K	20K	19K	21.4K
Common Stock Shares Outstanding	88.9M	101.7M	136.1M	137.0M	137.0M	143.8M
Liabilities And Stockholders Equity	205K	1.7M	2.3M	1.5M	976K	853.8K
Other Current Assets	16K	91K	7K	11K	38.0	36.1
Other Stockholder Equity	1.9M	816K	755K	358K	324K	0.0
Total Liab	788K	857K	585K	405K	85K	80.8K
Total Current Assets	110K	1.6M	2.3M	1.5M	976K	723.9K
Accumulated Other Comprehensive Income	3.6M	3.7M	3.8M	3.8M	4.2M	2.3M
Net Tangible Assets	435K	(583K)	804K	1.7M	2.0M	2.1M
Short Term Debt	29K	5K	6K	9K	8.1K	8.8K
Property Plant Equipment	62K	95K	27K	2K	1.8K	1.7K
Net Invested Capital	(583K)	804K	1.7M	1.1M	891K	612.2K
Net Working Capital	(667K)	777K	1.7M	1.1M	891K	573.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC